TA B L E 1 Valproic acid clinical studies
A rapid rebound in the patient's viral load and a decline of CD4+ T cell count was noted within 3 weeks of ART discontinuation
Siliciano et al 12 Cross-sectional, longitudinal study Treatment: VPA therapy (doses of 500-2500 mg/ day) for at least 3 months + combined ART for at least 3 mo with a viral load suppression to <50 copies/mL N = 9 Primary: Size of the latent reservoir for HIV-1 in resting CD4+ T cells measured by a wellcharacterized assay The levels of latently infected cells in the patients receiving ART and VPA were similar to those seen in patients receiving ART alone
Sagot-Lerolle et al 13 Single-centre pilot study Treatment: Group A: VPA (dose undefined) + combination ART Group B: combination ART N = 24 (11 in group A/ 13 in group B) Primary: The impact of prolonged VPA treatment on the HIV reservoir measured by a well-characterized assay an RT-PCR. Secondary: Rebound viraemia levels after the discontinuation of VPA therapy remains the current standard of care in HIV-infected patients. 2, 3 Investigators continue to explore novel therapeutic targets and treatment modalities, with an aim to discover methods which will lead to viral eradication in the future. 4 One novel strategy currently being investigated is utilization of drug therapy to reactivate the latently infected CD4+ T cells, without inducing universal T-cell activation that is thought to be detrimental to immune function. [5] [6] [7] In reactivating the latently infected CD4+ T cells, it is hypothesized that the HIV virus will initiate replication and then become susceptible to the therapeutic effects of combined ART, viral cytopathic effects and host cytolytic mechanisms of the immune system. 8 The primary target for many investigational latency-reversing agents is histone deacetylase 1, an enzyme which plays a role in transcription has been implicated in maintaining latency of HIV after viral integration. 9 Inhibition of this enzyme is postulated to reverse latency of these dormant reservoirs. Valproic acid (VPA) is a commonly prescribed agent with potential histone deacetylase inhibitory properties that has been investigated for latency-reversing properties and potential therapeutic effects in HIV-1 infection. 9, 10 The purpose of this review was to critically evaluate the available literature on innovative use of VPA for the agent's therapeutic effects on reversing latent HIV reservoirs. This evaluation is beneficial as potentially curative therapy primarily relies on the ability to target the latent reservoirs for eradication.
| ME THODS
A PubMed search (1996-December 2017) was conducted using Additionally, commentaries/opinion articles and studies which did not evaluate VPA's role as a latency-reversing agent were excluded.
Seven articles met criteria for review (Table 1) .
| RE SULTS
Lehrmen et al 9 conducted a proof-of-concept study in four HIV-1 infected patients on combined ART, who had long-term suppression of viraemia, defined as <50 copies/mL for more than 2 years.
Participants were ≥18 years of age and were required to comply with self-administered enfuvirtide (ENF) for up to 18 weeks in the study.
The primary objective was to investigate whether intensified combination ART, defined as the addition of ENF to a suppressive ART regimen, followed by the addition of VPA would accelerate clearance of HIV from latently infected CD4+ T cells. In the study, participants received intensified ART therapy with ENF dosed at 90 μg twice daily for 4-6 weeks followed by oral VPA dosed between 500 and 740 mg twice daily for a duration of 3 months. The VPA dose were included in this study if they were on a stably suppressed ART regimen with a viral load <50 copies/mL for more 2 years.
A total of 24 patients were included in this analysis. Eleven were on concomitant VPA for other comorbidities and combined ART, whereas 13 patients were treated with combined ART alone and comprised the control group. CD4+ T cells were quantified by real-time PCR methods, and total viraemia was measured using a quantified PCR. Investigators did not measure resting DR-CD4 cells, which may be more indicative of the size HIV latent reservoir.
There was no significant difference noted in the total amount of viraemia among the groups. Investigators also evaluated the rate of rebound viraemia in scheduled ART interruption trials (WINDOW, VACCIL-2 and SALTO) for patients receiving VPA for other indications. Three patients on VPA were noted with an increase in HIV RNA levels from <400 to values ranging from 13 000 to 60 000 copies/mL after 8 weeks of interruption. Two additional patients were noted with rebound viraemia despite VPA therapy, but the magnitude of rebound was not defined. Investigators concluded that viral reservoir size did not differ significantly among groups, and long-term VPA therapy appeared ineffective in reducing the HIV-1 latent reservoir. This study has some important limitations. The sample size was small, the VPA dose was not defined, the ART therapy utilized was not defined, and plasma VPA levels were only taken at baseline and the VPA dose was not adjusted according to plasma VPA levels. 13 Archin et al 14 conducted a prospective, clinical controlled trial study to detect the ability of VPA therapy to deplete resting CD4+
T cell in patients suppressed on ART, which included protease inhibitors, non-nucleoside reverse transcriptase inhibitors or both.
Twelve HIV-infected males who were stably suppressed on standard ART with an undetectable viral load (>50 copies/mL) and a CD4 cell count of more than 300 cells/μL for at least 6 months were enrolled in this study. Patients receiving zidovudine were excluded due to the drug interaction potential with VPA. One patient was excluded from review due to protocol violations. VPA (Depakote ER) was administered at 1000 mg daily × 6 weeks in combination with standard ART. Per the study protocol, VPA doses were uptitrated for trough levels consistently below 40 μg/mL. A VPA dose of 1250 mg was required for one patient. CD4+ T cells were isolated using leukapheresis and then measured using an outgrowth assay. The HIV-1 RNA concentrations were measured by reverse transcription polymerase chain reaction (RT-PCR). VPA combined with standard ART depleted resting cell infection (RCI) by more than 50% in four of the 11 study patients. Additionally, no correlation was noted between reduction in RCI and duration of aviraemia.
Investigators concluded that VPA did not demonstrate sufficient efficacy in reducing the latent HIV reservoir. This study has important limitations. The sample size was small, VPA treatment duration was relatively short, and consistent VPA therapeutic levels were not achieved during this study. unchanged. In the two non-responding VPA patients in index study with intensified baseline ART with ENF, there was no noted effect in their RCI. In the one newly enrolled patient who was started on VPA (Depakote ER) and RAL, a 46% decrease in RCI was noted.
However, this was not statistically significant as an RCI of 50% or greater was predetermined to be the threshold for significance. Of the seven patients in the parallel cohort, none of the patients experienced significant declines (>50%) in RCI and no significant effects on viraemia were noted. This study has several limitations including the small sample size, VPA formulations and dosage strengths (generic immediate-release and brand sustained-release) utilized, and inconsistencies in achieved VPA levels, which could confound the results. 15 Routy et al 16 T cell count ≥200 cells/ μL, and naïve to VPA therapy were eligible for inclusion. Twelve patients withdrew at some point during the study, with the most common reason cited for withdrawal being adverse events caused by VPA. Study participants were randomly assigned, in equal numbers, to receive either VPA and ART for 16 weeks followed by ART alone for 32 weeks (arm 1) or ART alone for 16 weeks followed by the addition of VPA to the regimen for 32 weeks (arm 2). The initial dose of VPA employed in the study was 500 mg × 1 day followed by an increase to 500 mg twice daily there was a notable amount of study attrition (21%). Additionally, the study observed the effects of VPA for 32 weeks of therapy, and there was no washout period in this cross-over study. 16 
| WHAT IS NE W AND CON CLUS I ON
Combined ART, when used effectively, has the potential to successfully suppress HIV-1 RNA plasma levels below the detection limitresulting in improvement in immune function, decreased morbidity and mortality, but no influence on viral eradication. 17 Currently, recommended combined ART regimens are comprised of three active antiretroviral agents from two pharmacologic classes, with different viral replication and/or entry targets. Although current drug therapy options may suppress HIV-1 RNA levels below the detection limit, no therapy has been demonstrated to effectively eliminate latent reservoirs, which are responsible for persistent HIV infection. 2, 3 Novel mechanisms are being explored to target and eliminate latent reservoirs, with the goal of viral cure.
In the current review, available literature was evaluated to determine efficacy, safety and clinical outcomes of repurposing VPA for an expanded indication in HIV infection. The majority of studies were small, ranging from a case report to a cohort of 56 patients. 9, [11] [12] [13] [14] [15] [16] All of the studies enrolled patients greater than 18 years of age, and the majority of the studies enrolled mostly men. 9, [11] [12] [13] [14] [15] [16] In addition, various assays to measure impact on latency were identified, including total viraemia assays, IUPM, RCI and CD4+ T cell quantification. 14, 15 In the study by Silicano et al, dose adjustments were made to maintain therapeutic benefit; however, therapeutic benefit was not defined. 12 Agents that comprised the combined ART therapy regimen varied among the studies, 9, [11] [12] [13] [14] [15] [16] and in the Sagot-Lerolle et al 13 , combined ART was not defined. Lehrmen et al suggested potential benefit of VPA in reversing viral latency; however, the study duration was short at 3 months with no evidence of retained clinical effects on the reservoirs. 9 All other articles reviewed did not demonstrate appreciable efficacy of VPA on viral latency.
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Although significant rates of adverse drug events were only noted in the Routy et al 16 study, there are two key therapeutic considerations with the use of VPA in the setting of HIV therapy and concomitant ART. Namely, VPA treatment-related adverse effects may lead to pharmacodynamic interactions with ART, such as thrombocytopenia, acute pancreatitis and hepatotoxicity. 18 Additionally, drug interaction potential must be considered given VPA's effects on CYP2C9 inhibition and CYP2A6 induction along with its property of being a substrate of several CYP enzymes, which when coupled with ART with varying CYP induction/inhibitory properties may lead to clinically significant drug interactions. To determine conclusively VPA's role in latency reversal, if any, further investigation is warranted. Until then, the quest for curative therapy continues.
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